JP2002528123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528123A5 JP2002528123A5 JP2000579757A JP2000579757A JP2002528123A5 JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5 JP 2000579757 A JP2000579757 A JP 2000579757A JP 2000579757 A JP2000579757 A JP 2000579757A JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- antigen
- sequence
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 description 40
- 239000003814 drug Substances 0.000 description 27
- 239000000427 antigen Substances 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 229940079593 drug Drugs 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000001461 cytolytic effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 244000053095 fungal pathogen Species 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10716998P | 1998-11-05 | 1998-11-05 | |
| US60/107,169 | 1998-11-05 | ||
| PCT/US1999/026291 WO2000026385A1 (en) | 1998-11-05 | 1999-11-05 | Nucleic acid constructs for genetic immunization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002528123A JP2002528123A (ja) | 2002-09-03 |
| JP2002528123A5 true JP2002528123A5 (enExample) | 2006-12-21 |
Family
ID=22315199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000579757A Pending JP2002528123A (ja) | 1998-11-05 | 1999-11-05 | 遺伝子免疫のための核酸構築物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1119630B1 (enExample) |
| JP (1) | JP2002528123A (enExample) |
| AT (1) | ATE315658T1 (enExample) |
| AU (1) | AU775939B2 (enExample) |
| CA (1) | CA2349505A1 (enExample) |
| CY (1) | CY1105600T1 (enExample) |
| DE (1) | DE69929470T2 (enExample) |
| DK (1) | DK1119630T3 (enExample) |
| ES (1) | ES2257879T3 (enExample) |
| IL (1) | IL142980A0 (enExample) |
| NZ (1) | NZ512078A (enExample) |
| PT (1) | PT1119630E (enExample) |
| WO (1) | WO2000026385A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933366B2 (en) | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
| US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| US6626871B1 (en) | 1999-10-11 | 2003-09-30 | Felton International, Inc. | Method and apparatus for removing cap from medical device |
| US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
| US20040054139A1 (en) * | 2000-06-22 | 2004-03-18 | Mark Page | Modification of hepatitis b core antigen |
| EP1354033A2 (en) * | 2000-09-19 | 2003-10-22 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| WO2002094313A2 (en) * | 2001-05-18 | 2002-11-28 | Powderject Vaccines, Inc. | Vaccine composition |
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| MXPA05003222A (es) * | 2002-09-27 | 2005-07-26 | Powderject Res Ltd | Particulas revestidas con acido nucleico. |
| US7335359B2 (en) | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
| WO2004069873A2 (en) | 2003-02-06 | 2004-08-19 | Tripep Ab | Antigen/antibody or ligand/receptor glycosylated specificity exchangers |
| AU2007306936B2 (en) | 2006-10-12 | 2014-02-06 | The University Of Queensland | Compositions and methods for modulating immune responses |
| EP2865389A1 (en) | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | IgE CH3 peptide vaccine |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| JP2013545453A (ja) | 2010-11-01 | 2013-12-26 | ユニバーシティ・オブ・テクノロジー、シドニー | 免疫変調剤およびそれらの使用 |
| KR101942372B1 (ko) * | 2011-02-11 | 2019-04-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | B형 간염 바이러스 코어 단백질을 암호화하는 핵산 분자 및 이를 포함하는 백신 |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
-
1999
- 1999-11-05 ES ES99963869T patent/ES2257879T3/es not_active Expired - Lifetime
- 1999-11-05 JP JP2000579757A patent/JP2002528123A/ja active Pending
- 1999-11-05 AT AT99963869T patent/ATE315658T1/de not_active IP Right Cessation
- 1999-11-05 PT PT99963869T patent/PT1119630E/pt unknown
- 1999-11-05 DK DK99963869T patent/DK1119630T3/da active
- 1999-11-05 DE DE69929470T patent/DE69929470T2/de not_active Expired - Lifetime
- 1999-11-05 AU AU20222/00A patent/AU775939B2/en not_active Ceased
- 1999-11-05 NZ NZ512078A patent/NZ512078A/xx not_active IP Right Cessation
- 1999-11-05 WO PCT/US1999/026291 patent/WO2000026385A1/en not_active Ceased
- 1999-11-05 IL IL14298099A patent/IL142980A0/xx unknown
- 1999-11-05 CA CA002349505A patent/CA2349505A1/en not_active Abandoned
- 1999-11-05 EP EP99963869A patent/EP1119630B1/en not_active Expired - Lifetime
-
2006
- 2006-04-07 CY CY20061100494T patent/CY1105600T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002528123A5 (enExample) | ||
| Ulrich et al. | Core particles of hepatitis B virus as carrier for foreign epitopes | |
| Celis et al. | Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen | |
| EP1685251B1 (en) | Nucleic acid constructs | |
| JP2004527213A5 (enExample) | ||
| CA2413546A1 (en) | Modification of hepatitis b core antigen | |
| JP2001512748A5 (enExample) | ||
| CA2305683A1 (en) | Immunogenic peptides from the hpv e7 protein | |
| US6492145B1 (en) | Vaccine against mycobacterial infections | |
| JP2002517249A5 (enExample) | ||
| CN1297481A (zh) | 向非人脊椎动物导入编码非人脊椎动物肽激素或细胞因子的裸dna或rna | |
| Morgan et al. | Comparative immunogenicity studies on Epstein‐Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton‐top tamarins | |
| EP0913157B1 (en) | A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method | |
| JP2004536107A5 (enExample) | ||
| CN118286410B (zh) | 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法 | |
| JP2002516662A5 (enExample) | ||
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| AU700104B2 (en) | Prolactin as a vaccine adjuvant | |
| CA2272051A1 (en) | Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation | |
| KR100905249B1 (ko) | Ｄｎａ와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션 | |
| Sanchez et al. | Evidence for the presence of repeating antigenic determinants in the major and minor polypeptides derived from hepatitis B surface antigen | |
| JP2021040627A5 (enExample) | ||
| JP2001517447A (ja) | Ｂ型肝炎ウイルスポリペプチド | |
| JP2021035361A5 (enExample) | ||
| Yong Kang et al. | Expression of Hepatitis B Virus Surface Antigen Gene in Mammalian, Yeast, and Insect Cells |